SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals - Quaterly Results

08 Feb 2024 Evaluate
The revenue for the December 2023 quarter is pegged at Rs. 1614.82 millions, about 8.52% up against Rs. 1488.04 millions recorded during the year-ago period.Net Profit for the quarter ended December 2023 zoomed to 142.13% from Rs. 50.27 millions to Rs. 121.72  millions.The company reported a good operating profit of 303.69 millions compared to 204.78 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 1614.82 1488.04 8.52 4634.65 3726.26 24.38 5220.51 5198.74 0.42
Other Income 14.91 22.14 -32.66 28.14 36.29 -22.46 48.86 51.98 -6.00
PBIDT 303.69 204.78 48.30 861.72 350.86 145.60 595.90 1196.83 -50.21
Interest 59.53 59.35 0.30 178.48 160.28 11.36 219.15 188.75 16.11
PBDT 244.16 145.43 67.89 683.24 190.58 258.51 376.75 1008.08 -62.63
Depreciation 80.09 81.25 -1.43 236.00 241.51 -2.28 321.25 321.52 -0.08
PBT 164.07 64.18 155.64 447.24 -50.93 -978.15 55.50 686.56 -91.92
TAX 42.35 13.91 204.46 112.22 -11.03 -1117.41 14.65 6.18 137.06
Deferred Tax 2.37 14.50 -83.66 7.24 -10.44 -169.35 14.69 -143.02 -110.27
PAT 121.72 50.27 142.13 335.02 -39.90 -939.65 40.85 680.38 -94.00
Equity 84.65 84.65 0.00 84.65 84.65 0.00 84.65 84.65 0.00
PBIDTM(%) 18.81 13.76 36.66 18.59 9.42 97.46 11.41 23.02 -50.42

SMS Pharmaceuticals Share Price

427.60 3.45 (0.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×